$ARMP

Armata Pharmaceuticals (NYSE American: ARMP) reported Q2 2026 results for the quarter ended June 30, 2026, with $2.5M grant and award revenue, R&D of about $7.6M, G&A of about $5.2M, and an operating loss of about $10.3M. The company said it submitted the Phase 3 protocol for AP-SA02 to the FDA, received Fast Track and an agreed pediatric study plan, and received an additional $2.5M non-dilutive DoD funding.

Armata Pharmaceuticals, Inc. (ARMP) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 armp-20260812xex99d1.htm EX-99.1 Exhibit 99.1 ​ Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update ​ LOS ANGELES, Calif., August 12, 2026 - Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “C

Biotech gainers included Zhengye Biotechnology (ZYBT), up about 1,048% after a Nasdaq bid-price noncompliance notice. Advanced Biomed (ADVB) rose over 70% after withdrawing a planned SEC-registered offering. Neuronetics (STIM) gained after naming a new CFO. Armata Pharmaceuticals (ARMP) advanced on Phase 3 AP-SA02 progress. Other movers: Profusa (PFSA), Ridgetech (RDGT), Turn Therapeutics (TTRX).

Armata Pharmaceuticals said it submitted the complete Phase 3 protocol for its AP-SA02 multi-phage therapy to the FDA, addressing End-of-Phase 2 feedback, and completed four engineering runs at its Los Angeles cGMP facility. The Phase 3 superiority study is planned to start in 2H 2026. The company received a $2.5M DoD continuation award. ARMP shares were up 10.27% to $4.97.

Armata Pharmaceuticals, Inc. (ARMP) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 tm2620782d1_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 Armata Pharmaceuticals, Inc. 5005 McConnell Ave Los Angeles, California 90066 July 17, 2026 Dear David: This letter agreement (this “ Agreement ”) is intended to confirm our mutual agreement with respect to your continued

Armata Pharmaceuticals (ARMP) said the U.S. FDA agreed to its Initial Pediatric Study Plan for AP-SA02 in pediatric complicated Staphylococcus aureus bacteremia. The iPSP sets a framework to defer pediatric work until adult Phase 3 data, expected to start in H2 2026, then run a single multicenter open-label pediatric trial. ARMP shares closed July 10 at $4.26.

Armata Pharmaceuticals, Inc. (ARMP) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0000921114 0000921114 2026-06-11 2026-06-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report

This article highlights 12 healthcare stocks experiencing significant price movements in Tuesday's pre-market session. It lists top gainers including Liminatus Pharma, CDT Equity, and DaVita, noting their percentage increases and market capitalizations. Conversely, it identifies key losers such as Armata Pharmaceuticals, Avanos Medical, and Kairos Pharma, detailing their respective percentage decreases and market values.

Armata Pharmaceuticals (ARMP) delivered earnings and revenue surprises of 0.00% and -16.01%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Here is how Armata Pharmaceuticals, Inc. (ARMP) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.